Ident,fied in 0 CFR 35.200 A,jcidentifiedin10'CFR 35.200 ...

[Pages:21]i

.

.

NRC FORM 374

U.s. NUCLEAR REGULATORY CoMMisSloN

PAGE

1 oF 3 PAGEs

Amendment No. 20

h

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, | of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36,39,40, and 70, and in reliance on statements and representations | heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer bypro.

source, and special nuclear material designated below; to use such material for the purpose (s) and at the place (s) designated belo

deliver or transfer such materialto persons authorized to receive it in accordance with the regulations of the applicable Part(s). This licen

shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to a

i

I

applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any con

below.

Licensee

In accordance with letter dated

December 17,1998 1

f '

'

1. Mercy Health Systems Oklahoma

3. License number 35-00957-02 is amended in

!

l

)

i

dba Mercy Memorial Health Center

e its eDtirety to read as follows:

3 r, -

sO" 2.1011 Fourteenth Avenue, N.W. Ardmore, Oklahoma 73401

t, ^

s

4: Eipiratiop date December 31,2002 5. DocketNar03002874

Reference No.

,

|

6. Byproduct, source, and/or special'e'a nuclear material

~.

A. Any byproduct mater $i'

7. Chemical and/or physical form

8 M'aximum amount that licensee may

. . . - possess at any one time under this

_

s.. 3

v

,- ,

./

4. gAnysradiopha,rmaceuticaP

license

_

A. As needed

-

!

B.

identified in 10 CFR'35.100 H

Any byproduct material

t sidentified'1n 10 CFR 35L100

B^: i

An( (eca, di64

Lt

pharmaceuticaBl.

a

ident,fied in 0 CFR 35.200 A,jcidentifiedin10'CFR 35.200-

Z

:,3s

22

needed

- g , s.

p

y

/y C. Any byproduct material"

g identified in 10 CFR 31.t1

-

g

' ? Pfehckaged KilsMM4C,-.6JAs needed

,

)

'

D. lodine-131

;y $. idem L-h

D$ 30 millicuries

9

'

|

E. Uranium depleted in

Uranium-235

|

,

F. Gadolinium-153 |

O E. Cadmiunfplated metal ?

g

a

y 4

-

7

F. Sealed sources (North American Scientific, Inc.

E. As needed

F. 300 millicuries per housing, total possession 1 curie

Model MED 3601 or DuPont

Merck Model NES-8412)

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200. C. In vitro studies. D. Diagnosis and treatment of hyperthyroidism and cardiac dysfunction. E. Shielding in a linear accelerator. F. For use in an ADAC Laboratories Model Vantage line source housing for SPECT cameras.

p

'

290035

9907290135 990707

PDR ADOCK 03002874

C

PDR

[

OFFICIAL RECORD COPY

QQ

NRC FoR[1374A

U.s NUCLEAR REGULATORY CoMMISsloN Lic:;nsa Number

35-00957-02

PAGE 2

MATERIALS LICENSE

SUPPLEMENTARY SHEET

D eket or Reference Number

03002874

Amendment No. 20

of 3 PAGEs

CONDITIONS

.

10. Location of use: 1011 Fourteenth Avenue, Northwest, Ardmore, Oklahoma.

11. Radiation Safety Officer: James A. Chapman, M.D.

12. Authonzed Users:

c. p.B R E G ,,

A. James A. Chapman, M.D., for materials identified in 10'CfiR 35.100, 35.200, and 31.11; iodine-131

for treatment of hyperthy[oipsm' and cardiac dysfunction; d'eplSted uranium; and gadolinium-153.

B. Hwan Youn, M.D., for rnYterials identified in 10 CFR 35.100, 35.200,and 31,11; iodine-131 for

treatment of hyperthyroidism and cardiac dysfunction; depleted urahium; and gadolinium-153.

Q f Q ~.,

"

~

#

/

C. Hernando Orjuela/Al.D., for m,ateria identified in 10 CFR 35,200 for nucl, ear cardiology.

,

H

Q:f '

,.

. ..

em

'-f;_.'

.': | )

,

..

.

t, J

n

-

13. In addition to the possession limits in item 8, tha liransee shall further restrict-the possession of licensed

material to quantities below the micirhum'liinifspe6fliiid:in 10 CFR30.35(d):for establishing

" " ~ ~

ff(hMi decommissioning financial assuqceh -

,-

.

Z~ ' j.

f

;~

,/ ,

,%. 3.Cr.n~'

,

,V

.i

%

*k

'~

u

. <

.

N 'a

.

-

,

*,

NRC FORM 374A

u.s. NUCLEAR i:EcVLAToRY co4' Mission

PAGE 3

License Number

35-00957-02

MATERIALS LICENSE

SUPPLEMENTARY SHEET

D eket r Reference Number

03002874

Amendment No. 20

of 3

PAGEs

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in

accordance with the statements, representations, and procedures contained in the documents, including

I

any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as

i

provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless

the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated September 24,4990,S b b C

B. Letter dated November 23,1992,.D

/

C. Letter dated November 30d992

'4x

D. Letter dated February {tf994

'r

E. Facsimile dated March 1'7,1994

U

.<

F. Facsimile and letter dated September 26,1994

'

-

i

G. Letter dated Augusf 19W s.,

/~ ^

'

H. l. J. K.

(3 LLLeeettttteetrerdrdaatdetdeadJteuOndecytD,o1b9ee9c8re4r,1n9b9.eR(?r:(1D7'%,e1' 998-

.. d

].yf

^

Q_

.

Letter dated June 31999

-

'

' g-

t

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download